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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2303The Relationships Between Microalbuminuria, Metabolic Syndrome, CKD, and CHDFreij Gobal, Abhishek Deshmukh, Sudhir Shah, Jawahar L. Mehta
Gobal and colleagues review the emerging evidence for the association, interaction, and
multiplier effect between the metabolic syndrome, chronic kidney disease (CKD), and
coronary heart disease (CHD). Several investigators have shown that hypertension,
dyslipidemia, and insulin resistance are associated with renin-angiotensin-system activation
and the generation of reactive oxygen species. This may result in oxidation of low-density
lipoprotein cholesterol and further microalbuminuria. This activation and inflammation results
in further endothelial injury, smooth muscle cell migration/proliferation, and eventually,
cardiac and renal fibrosis.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY2309Bivalirudin Improves Outcomes in STEMI Patients Pre-Treated With HeparinGeorge D. Dangas, Roxana Mehran, Eugenia Nikolsky, Bimmer E. Claessen, Alexandra J. Lansky,
Bruce R. Brodie, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Dariusz Dudek,
Martin Möckel, Adriano Caixeta, Helen Parise, Harvey White, Gregg W. Stone, for the
HORIZONS-AMI Trial Investigators
Unfractionated heparin (UFH) is frequently administered early in ST-segment elevation
myocardial infarction (STEMI), and whether the efficacy and safety of bivalirudin
documented in the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial persist in patients previously administered UFH
is the focus of this pre-specified subgroup analysis. Dangas and colleagues analyzed the
outcomes of the patients in the HORIZONS-AMI trial who were treated with UFH before
randomization, one-half of whom were randomized to bivalirudin and one-half to further
UFH plus a glycoprotein (GP) IIb/IIIa inhibitor. Those assigned to bivalirudin had lower
30-day mortality, lower rates of major bleeding, and lower rates of reinfarction. In patients
with STEMI who receive early treatment with UFH, switching to bivalirudin for primary
percutaneous coronary intervention improves outcomes.(continued on page A-22)
JUNE 7, 2011 (continued) A-22HEART RHYTHM DISORDERS2317Distinguishing ARVC-Associated Mutations From Background Genetic NoiseJamie D. Kapplinger, Andrew P. Landstrom, Benjamin A. Salisbury, Thomas E. Callis, Guido D. Pollevick,
David J. Tester, Moniek G. P. J. Cox, Zahir Bhuiyan, Hennie Bikker, Ans C. P. Wiesfeld,
Richard N. W. Hauer, J. Peter van Tintelen, Jan D. H. Jongbloed, Hugh Calkins, Daniel P. Judge,
Arthur A. M. Wilde, Michael J. Ackerman
Kapplinger and colleagues investigated the spectrum and frequency of genetic variation among
the susceptibility genes for arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC) in patients and healthy controls to determine the “genetic noise” associated with the
ARVC genetic test. A total of 16% of healthy controls were found to have a mutation in 1 of
these genes compared with 58% of cases. The mutations in controls were usually missense
mutations, while 43% of ARVC cases hosted radical mutations. Relative to controls,
mutations in ARVC cases tended to localize to certain “hot spots” of functional significance.
This is the first comprehensive study of genetic variation in healthy controls for the ARVC-
susceptibility genes and demonstrates that missense mutations may not indicate increased risk
of ARVC.Editorial Comment: Luisa Mestroni, Matthew R. G. Taylor, p. 2328HEART RHYTHM DISORDERS2330Methods for Determining ICD Lead Fractures From Connection ProblemsCharles D. Swerdlow, Haresh Sachanandani, Bruce D. Gunderson, Kevin T. Ousdigian, Mark Hjelle,
Kenneth A. Ellenbogen
Implantable cardioverter-defibrillator (ICD) diagnostics facilitate identification of lead
fractures, but there are no accepted criteria for discriminating fractures from other causes of
high impedance and/or nonphysiological “noise” oversensing. Swerdlow and colleagues
analyzed 91 leads that triggered high-impedance alerts to construct a stepwise algorithm. In
the algorithm, either extremely high maximum impedance or noise oversensing with a normal
impedance trend indicated a fracture. A short interval from surgery to impedance rise or a
prolonged stable impedance after an abrupt rise indicated a connection problem. A gradual
impedance increase or stable, high impedance was found in functioning leads. This algorithm
can help to determine the etiology of high-impedance alerts and may avoid unnecessary lead
replacement procedures.(continued on page A-25)
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2340Low Prevalence of Risk Markers in Cases of
Sudden Death Due to Brugada SyndromeHariharan Raju, Michael Papadakis, Malini Govindan, Rachel Bastiaenen, Navin Chandra,
Ann O’Sullivan, Georgina Baines, Sanjay Sharma, Elijah R. Behr
Raju and colleagues analyzed reported symptoms and reviewed electrocardiograms (ECGs)
from sudden arrhythmic death syndrome (SADS) probands with a familial diagnosis of
Brugada syndrome (BrS). A total of 49 families with a confirmed SADS death and a
diagnosis of BrS in 1 or more family members were evaluated. ECGs prior to death were
available in 5 SADS probands, 1 of which demonstrated a spontaneous type 1 pattern. Only
20% of probands had suffered at least 1 syncopal episode before the fatal event; 68% of
probands would not have fulfilled any current criteria for consideration of implantable
cardioverter-defibrillator implantation in BrS patients. These findings question the adequacy
of current methods of risk stratification in patients with BrS.CARDIOMYOPATHY2346MVO Predicts Worse Outcomes in Patients With HCMYuichiro Minami, Katsuya Kajimoto, Yutaka Terajima, Bun Yashiro, Dai Okayama, Shintaro Haruki,
Takatomo Nakajima, Naomi Kawashiro, Masatoshi Kawana, Nobuhisa Hagiwara
In most patients with hypertrophic cardiomyopathy (HCM), if there is an obstruction to
flow, it occurs at the subaortic level, mainly due to systolic anterior motion of the anterior
mitral valve leaflet. In a minority of HCM patients, however, the impedance to flow occurs at
the midcavitary level and is predominantly caused by marked septal hypertrophy coming into
contact with a hypercontractile left ventricular free wall. Minami and colleagues investigated
the prevalence, clinical characteristics, and prognosis of HCM patients with midventricular
obstruction (MVO), diagnosed when the peak midcavitary gradient was estimated to be 30
mm Hg. MVO was present in 9.4% of patients who were more likely to be symptomatic and
were at increased risk of HCM-related death in multivariate models. MVO is a marker of
increased risk in patients with HCM.(continued on page A-26)
JUNE 7, 2011 (continued) A-26PERIPHERAL ARTERIAL DISEASE2356Sedentary Hours and Walking Speed Predict Functional Declines in Patients With PADMary M. McDermott, Kiang Liu, Luigi Ferrucci, Lu Tian, Jack M. Guralnik, Yihua Liao,
Michael H. Criqui
McDermott and colleagues studied the associations between sedentary behavior and walking
speed with functional decline and changes in calf muscle characteristics in patients with lower
extremity peripheral arterial disease (PAD). At baseline, participants reported the number of
hours they spent sitting per day and their walking speed outside their home. After adjusting
for confounders, slower walking speed outside the home was associated with faster annual
decline in calf muscle density, 6-min walk distance, and 4-m walking velocity. Sedentary
hours per day and walking speed may be targets for intervention that can blunt the functional
decline in patients with PAD.Editorial Comment: Mehdi H. Shishehbor, p. 2365CONGENITAL HEART DISEASE2368Transfer of Adolescents With CHD From Pediatric to Adult CardiologyEva Goossens, Ine Stephani, Deborah Hilderson, Marc Gewillig, Werner Budts, Kristien Van Deyk,
Philip Moons, on behalf of the SWITCH2 Investigators
Goossens and colleagues examined the transfer of adolescents with congenital heart disease
(CHD) from pediatric to adult care in Belgium by performing a descriptive, observational
study of almost 800 patients with CHD. A total of 7% of the patients were not in follow-up.
According to international guidelines, 10% did not receive the minimal level of cardiac care.
Multivariable logistic regression revealed that male sex and no prior heart surgery were
associated with “no follow-up.” The proportion of patients lost to follow-up was substantially
lower than in previous reports, but further examination of patient-, hospital-, and healthcare-
related determinants of lack of follow-up is warranted.
